2022
Gender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisordersFactors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.Peer-Reviewed Original ResearchConceptsOpioid use disorderHigher pain interferenceMOUD retentionPain interferenceUse disordersOngoing prospective cohort studySevere opioid use disorderProspective cohort studyMultivariable logistic regressionCohort of adultsMethadone doseAnalgesic effectBuprenorphine doseCohort studyOpioid useResultsA totalHigher oddsMOUDAdjusted modelHigh doseLogistic regressionBuprenorphineMethadoneDoseDiscontinuation
2021
Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence
Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.Peer-Reviewed Original ResearchOpioid use disorderHIV-1 persistenceHIV persistenceCohort studyHIV infectionMedication treatmentLimited bloodUse disordersProviral landscapeDSM-5 opioid-use disordersExtended-release naltrexoneProspective cohort studyHIV-1 expressionPartial agonist buprenorphineLongitudinal studyHIV continuumMonth 3Clonal expansion dynamicsMOUDDifferential biological effectsStudy participantsHIVMolecular virologyBloodBuprenorphineDesign and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder
Biondi BE, Mohanty S, Vander Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemporary Clinical Trials Communications 2021, 21: 100704. PMID: 33490708, PMCID: PMC7807244, DOI: 10.1016/j.conctc.2021.100704.Peer-Reviewed Original ResearchOpioid use disorderProspective cohort studyHIV infectionCohort studyMedication treatmentUse disordersDSM-5 opioid-use disordersLongitudinal studyBiological effectsHIV continuumMonth 6Immune responseDifferential biological effectsMOUDHIVSystems biology approachInfectionTreatmentDSM-5DisordersPersonsBiology approachMedicationsBuprenorphineMethadone
2020
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder
Cioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. Journal Of Substance Use And Addiction Treatment 2020, 119: 108146. PMID: 33138929, PMCID: PMC7609980, DOI: 10.1016/j.jsat.2020.108146.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid epidemicProvider perspectivesUse disordersSystematic reviewType of MOUDExtended-release naltrexoneNumber of patientsOutcomes of interestPubMed database searchReview eligibility criteriaPatient themesPublic health crisisPatient retentionMOUDEligibility criteriaPatientsProviders' perceptionsFinal reviewLack of trainingMedicationsBuprenorphineNaltrexoneMethadoneHealth crisisThe Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review
Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review. Infectious Disease Clinics Of North America 2020, 34: 559-584. PMID: 32782102, PMCID: PMC7437982, DOI: 10.1016/j.idc.2020.06.011.Peer-Reviewed Original ResearchA Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?
Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? American Journal On Addictions 2020, 29: 249-267. PMID: 32346932, PMCID: PMC7377168, DOI: 10.1111/ajad.13051.Peer-Reviewed Original ResearchConceptsUrine drug testsOpioid usePrimary outcomeOpioid use disorderTreatment studiesTreatment successUse disordersMedication treatment studiesOpioid treatment outcomesDifferent primary outcomesClinical trialsOpioid outcomesTreatment outcomesInclusion criteriaOutcome measuresLiterature reviewDrug testsOutcomesDisordersTreatmentReviewMedicationsMOUDStudyClinicians
2019
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
Fanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.Peer-Reviewed Original ResearchConceptsOpioid use disorderExtended-release naltrexoneHIV treatment outcomesHIV viral suppressionViral suppressionUse disordersAntiretroviral therapyTreatment outcomesCurrent US opioid epidemicOptimal HIV treatment outcomesUS opioid epidemicOverall mortalityHIV outbreakHIV treatmentOpioid epidemicMOUDHIVMedicationsDisordersNaltrexoneDelivery characteristicsTherapyTreatmentIncarcerated settingsOutcomes